NCT06090721

DMT310-009 Topical in the Treatment of Acne Vulgaris

Name: Clinical Trial NCT06090721
Creator: Dermata Therapeutics
Keywords: Acne Vulgaris, DMT310, Phase 3, drug, clinical trial

A PHASE 3 STUDY OF TOLERABILITY, SAFETY, AND EFFICACY, OF DMT310 IN PATIENTS WITH ACNE VULGARIS

Dermata Therapeutics·Phase 3·ClinicalTrials.gov·drugNot yet recruiting

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Acne Vulgaris
Drug/Device/Intervention: DMT310
Study type: Interventional
Intervention type: drug

Sponsor & location

Primary sponsor: Dermata Therapeutics

Timeline & enrollment

Phase: Phase 3
Start date: Oct 01, 2023
End date: Oct 01, 2024
Enrollment: 555 participants

Primary outcome

Efficacy as measured by lesion counts,Efficacy as measured by Investigator Global Assessment (IGA)

Summary

The objective is to evaluate the tolerability, safety, and efficacy of DMT310 topical powder mixed with diluent in male and female patients with moderate to severe facial acne vulgaris

ICD-10 classifications

Acne vulgarisAcneAcne, unspecifiedAcné excoriéeOther acne

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT06090721
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT06090721 through Pure Global AI's free database. This Phase 3 trial is sponsored by Dermata Therapeutics and is currently Not yet recruiting. The study focuses on Acne Vulgaris. Target enrollment is 555 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.